 LAUSANNE, Switzerland--BUSINESS WIRE--ADC Therapeutics SA NYSE:ADCT, a commercial-stage biotechnology company leading the development of novel antibody drug conjugates ADCs to treat hematological malignancies and solid tumors, today announced that shareholders approved all of the resolutions as proposed by the Board of Directors at yesterdays Annual General Meeting AGM. Election of new Board member Viviane Monges Shareholders approved the election of Viviane Monges to the board of dire 